• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

    2/14/23 4:35:55 PM ET
    $SBTX
    Specialty Chemicals
    Consumer Discretionary
    Get the next $SBTX alert in real time by email
    SC 13G/A 1 tm236482d1_sc13ga.htm SC 13G/A

     

     

         
      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    ARS Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    82835W 10 8

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    ¨ Rule 13d-1(c)
       
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.  82835W 10 8
     
      1. Names of Reporting Persons
    Nextech VI Oncology SCSp
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Luxembourg
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    1,910,029 shares
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    1,910,029 shares
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,029 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    2.0% (2)
     
      12. Type of Reporting Person (See Instructions)
    PN
               

     

    (1)This Schedule 13G is filed by Nextech VI Oncology SCSp (“Nextech VI LP”), Nextech VI GP S.à. r.l. (“Nextech VI GP”), Rocco Sgobbo (“Sgobbo”), Dalia Bleyer (“Bleyer”) and Ian Charoub (“Charoub” and together with Nextech VI LP, Nextech VI GP, Sgobbo and Bleyer, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

     

     

     

    CUSIP No.  82835W 10 8
     
      1. Names of Reporting Persons
    Nextech VI GP S.à r.l.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Luxembourg
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    1,910,029 shares
     
    6. Shared Voting Power
    0
     
    7. Sole Dispositive Power
    1,910,029 shares
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,029 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    2.0% (2)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

     

     

     

    CUSIP No.  82835W 10 8
     
      1. Names of Reporting Persons
    Rocco Sgobbo
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Switzerland
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,910,029 shares
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,910,029 shares
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,029 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    2.0% (2)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

     

     

     

    CUSIP No.  82835W 10 8
     
      1. Names of Reporting Persons
    Dalia Bleyer
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Lithuania
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,910,029 shares
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,910,029 shares
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,029 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    2.0% (2)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

     

     

     

    CUSIP No.  82835W 10 8
     
      1. Names of Reporting Persons
    Ian Charoub
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Sweden
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,910,029 shares
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,910,029 shares
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,029 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    2.0% (2)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

     

     

     

    Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”) of ARS Pharmaceuticals, Inc. f/k/a Silverback Therapeutics, Inc.(the “Issuer”).
     
    Item 1.
     
      (a)

    Name of Issuer:

     

    ARS Pharmaceuticals, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices:

     

    11682 El Camino Real, Suite 120

    San Diego, California 92130

     
    Item 2.
     
      (a)

    Name of Reporting Persons Filing:

     

    Nextech VI Oncology SCSp (“Nextech VI LP”)

    Nextech VI GP S.à r.l. (“Nextech VI GP”)

    Rocco Sgobbo (“Sgobbo”)

    Dalia Bleyer (“Bleyer”)

    Ian Charoub (“Charoub”)

      (b)

    Address of Principal Business Office or, if none, Residence:

     

    8 rue Lou Hemmer

    L-1748 Luxembourg-Findel

    Grand-Duché de Luxembourg

      (c)

    Citizenship

     

        Name Citizenship or Place of Organization
        Nextech VI LP Luxembourg
        Nextech VI GP Luxembourg
         
        Sgobbo Switzerland
        Bleyer Lithuania
        Charoub Sweden
      (d)

    Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share

      (e)

    CUSIP Number:

     

    82835W 10 8

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

    Item 4.Ownership

     

    The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2022.    

     

    Reporting Persons  Shares of
    Common Stock
    Held Directly
      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power (1)

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power (1)

      

    Beneficial

    Ownership

      

    Percentage

    of Class (1) (2)

     
    Nextech VI LP   1,910,029    1,910,029    0    1,910,029    0    1,910,029    2.0%
    Nextech VI GP (1)   0    1,910,029    0    1,910,029    0    1,910,029    2.0%
    Sgobbo (1)   0    0    1,910,029    0    1,910,029    1,910,029    2.0%
    Bleyer (1)   0    0    1,910,029    0    1,910,029    1,910,029    2.0%
    Charoub (1)   0    0    1,910,029    0    1,910,029    1,910,029    2.0%

     

    (1)The shares are held by Nextech VI LP. Nextech VI GP serves as the sole general partner of Nextech VI LP and has sole voting and investment control over the shares owned by Nextech VI LP and may be deemed to own beneficially the shares held by Nextech VI LP. Nextech VI GP owns no securities of the Issuer directly. Sgobbo, Bleyer and Charoub are members of the board of managers of Nextech VI GP and share voting and dispositive power over the shares held by Nextech VI LP, and may be deemed to own beneficially the shares held by Nextech VI LP. The managing members own no securities of the Issuer directly.

     

    (2)The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☒.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
    Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
    Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
    Not applicable
     
    Item 9. Notice of Dissolution of Group
       
    Not applicable
     
    Item 10. Certification
       
    Not applicable

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

    Nextech VI Oncology SCSp
         
    By: Nextech VI GP S.à r.l.  
    its General Partner  
         
    By: /s/ Dalia Bleyer  
      Dalia Bleyer, Managing Member  
         
    By: /s/ Rocco Sgobbo  
      Rocco Sgobbo, Managing Member  
         
    Nextech VI GP S.à r.l.
         
    By: /s/ Dalia Bleyer  
      Dalia Bleyer, Managing Member  
         
    By: /s/ Rocco Sgobbo  
      Rocco Sgobbo, Managing Member  
         
    /s/ Rocco Sgobbo  
    Rocco Sgobbo  
         
    /s/ Dalia Bleyer  
    Dalia Bleyer  
         
    /s/ Ian Charoub  
    Ian Charoub  

     

     

    Get the next $SBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBTX

    DatePrice TargetRatingAnalyst
    4/4/2022$25.00 → $3.50Buy → Neutral
    Goldman
    4/1/2022$25.00 → $1.80Outperform → Mkt Perform
    SVB Leerink
    4/1/2022$32.00 → $6.00Buy → Hold
    Stifel
    4/1/2022Buy → Neutral
    H.C. Wainwright
    11/12/2021$42.00 → $25.00Outperform
    SVB Leerink
    8/16/2021$46.00 → $49.00Outperform
    SVB Leerink
    More analyst ratings

    $SBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/9/24 8:35:56 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/25/23 4:30:47 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/1/23 4:15:58 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

      SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve

      3/15/21 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SBTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SBTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

      Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle

      11/10/22 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

      Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus

      11/8/22 4:02:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

      neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U

      10/21/22 7:31:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      10/2/23 4:23:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/25/23 4:30:22 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously

      4/4/22 7:33:52 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously

      4/1/22 9:04:51 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously

      4/1/22 7:22:09 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:53:49 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Karas Eric

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:47:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:45:07 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Financials

    Live finance-specific insights

    See more
    • Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

      Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap

      7/21/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

      - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron

      3/31/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

      – Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu

      9/16/21 3:30:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Silverback Therapeutics Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:04:53 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:02:29 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      9/25/23 4:17:04 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary